Active substance
Suvorexant
- US FDA 1
- US price lines 4
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BELSOMRA | 5MG; 10MG; 15MG; 20MG | tablet · oral | MERCK SHARP DOHME | Prescription | 13 Aug 2014 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BELSOMRA 10 MG TABLET | $15.21275 | per EA | 23 Sep 2026 |
| US NADAC | BELSOMRA 15 MG TABLET | $15.19058 | per EA | 23 Sep 2026 |
| US NADAC | BELSOMRA 20 MG TABLET | $15.20528 | per EA | 23 Sep 2026 |
| US NADAC | BELSOMRA 5 MG TABLET | $15.20133 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 10 Mar 2025 BELSOMRA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.